MORRISTOWN, N.J. — A well-controlled human clinical trial comparing standard curcumin and several commercial curcumin products with enhanced bioavailability showed CurcuWIN™ from OmniActive Health Technologies significantly increased serum curcuminoid levels 46 times over standard curcumin. CurcuWIN was also shown to be significantly more bioavailable than other enhanced curcumin ingredients. The randomized, double-blind crossover study entitled “Comparative Absorption of Curcumin Formulations” was conducted by the University of Tampa in collaboration with Increnovo LLC, a leading contract research and consulting company supporting scientific, clinical research and product development in the dietary supplement and food and beverage categories. The study showed an increase in serum levels of total curcuminoids (curcumin, demethoxycurcumin, bisdemethoxycurcumin) and the metabolite tetrahydrocurcumin after oral administration of three different curcumin formulations and an unformulated standard curcumin. Results were published by Nutrition Journal on January 24. Click here to view the full study.
“Because this study was designed to have participants serve as their own control, a direct comparison could be made between the bioavailability of the curcumin ingredients tested,” noted Jayant Deshpande, Ph.D., Chief Technical Officer, OmniActive Health Technologies. “No other product has gone through this degree of testing in such a robust bioavailability model alongside multiple product forms. Now that we have established CurcuWIN’s superior bioavailability and conducted preclinical studies, we plan additional clinicals to support its efficacy.”
Twelve healthy individuals completed the study, testing each curcumin form under fasting conditions with a washout period between dosing. Standard FDA proposed bioavailability measures including AUC, Tmax, Cmax and relative absorption were conducted, and a more robust, conservative and rigorous statistical model was used to provide lower variability in the results. What made this particular study both unique and relevant is that it tested a bioavailable curcumin ingredient, in this case CurcuWIN, not only against standard curcumin but also against other enhanced curcumin products on the market.
OmniActive utilized its patented UltraSOL™ Dry Nutrient System Technology, a molecular dispersion process that enhances the solubility and bioavailability of lipophilic compounds and poorly absorbed nutrients, to develop CurcuWIN Turmeric Extract Powder. Patent-pending CurcuWIN provides 20 percent curcuminoids in the ratio in which they are naturally found in turmeric.
About OmniActive Health Technologies, Inc.
OmniActive Health Technologies (www.omniactives.com) offers a range of quality ingredients, which are innovative and scientifically validated for dietary supplementation, nutritional fortification, functional food/beverage, coloring, flavor enhancement and personal care applications. The company addresses complex challenges for customers in the dietary supplement, food and beverage space using technology-driven, sustainable solution with application support within a global regulatory framework. Whether looking for a new ingredient to add to a finished product, or technology to enhance an existing ingredient, find unmatched innovation at OmniActive
Core products are carotenoids, spice, plant extracts and specialty functional ingredients. OmnActive leverages international R&D strengths to deploy an array of state of the art manufacturing technologies in extraction, purification, isolation and delivery of nutritional actives. The company’s manufacturing operations are located at multiple sites in India and are cGMP and HACCP compliant.
About Nutrition Journal
Nutrition Journal is a high quality, peer-reviewed journal with universal access to its content from virtually any place in the world. Studies published in Nutrition Journal are included in PubMed, the most widely used biomedical bibliographic database service run by the US National Library of Medicine. Nutrition Journal is tracked by Thomson Reuters (ISI) and has an Impact Factor of 2.65.